TW297093B - - Google Patents
Download PDFInfo
- Publication number
- TW297093B TW297093B TW082111061A TW82111061A TW297093B TW 297093 B TW297093 B TW 297093B TW 082111061 A TW082111061 A TW 082111061A TW 82111061 A TW82111061 A TW 82111061A TW 297093 B TW297093 B TW 297093B
- Authority
- TW
- Taiwan
- Prior art keywords
- amino acid
- blood
- cells
- group
- cell
- Prior art date
Links
- 235000001014 amino acid Nutrition 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 40
- 210000000601 blood cell Anatomy 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 238000005259 measurement Methods 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 210000000170 cell membrane Anatomy 0.000 claims description 15
- -1 alkenyl alkane Chemical class 0.000 claims description 14
- 230000000366 juvenile effect Effects 0.000 claims description 14
- 230000003204 osmotic effect Effects 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 5
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 4
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 4
- 244000125380 Terminalia tomentosa Species 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- STVGXWVWPOLILC-LUQRLMJOSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl decanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 STVGXWVWPOLILC-LUQRLMJOSA-N 0.000 claims 1
- KTYVHLCLTPLSGC-UHFFFAOYSA-N amino propanoate Chemical compound CCC(=O)ON KTYVHLCLTPLSGC-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical class Cl* 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 claims 1
- SGCKSDJIMSBTFY-UHFFFAOYSA-N n-sulfonylformamide Chemical compound O=CN=S(=O)=O SGCKSDJIMSBTFY-UHFFFAOYSA-N 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 235000004252 protein component Nutrition 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 description 61
- 229940024606 amino acid Drugs 0.000 description 40
- 239000012190 activator Substances 0.000 description 22
- 210000002798 bone marrow cell Anatomy 0.000 description 19
- 238000000034 method Methods 0.000 description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 16
- 210000003743 erythrocyte Anatomy 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 235000006109 methionine Nutrition 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 210000003969 blast cell Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229940071204 lauryl sarcosinate Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- 239000004470 DL Methionine Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940005605 valeric acid Drugs 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 210000003887 myelocyte Anatomy 0.000 description 2
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- NGEWQZIDQIYUNV-UHFFFAOYSA-N L-valinic acid Natural products CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000018779 Replication Protein C Human genes 0.000 description 1
- 108010027647 Replication Protein C Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- QRZVZQKAGDFAFF-UHFFFAOYSA-N azane;butane-2,3-dione Chemical compound N.CC(=O)C(C)=O QRZVZQKAGDFAFF-UHFFFAOYSA-N 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/1031—Investigating individual particles by measuring electrical or magnetic effects
- G01N15/12—Investigating individual particles by measuring electrical or magnetic effects by observing changes in resistance or impedance across apertures when traversed by individual particles, e.g. by using the Coulter principle
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/2525—Stabilizing or preserving
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Ecology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06003793A JP3301646B2 (ja) | 1993-03-19 | 1993-03-19 | 幼若細胞測定用試薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW297093B true TW297093B (de) | 1997-02-01 |
Family
ID=13130481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW082111061A TW297093B (de) | 1993-03-19 | 1993-12-28 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5413938A (de) |
| EP (1) | EP0617281B1 (de) |
| JP (1) | JP3301646B2 (de) |
| KR (1) | KR100287583B1 (de) |
| CN (1) | CN1088194C (de) |
| AU (1) | AU665508B2 (de) |
| CA (1) | CA2119390C (de) |
| DE (1) | DE69419053T2 (de) |
| ES (1) | ES2132352T3 (de) |
| TW (1) | TW297093B (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3467310B2 (ja) * | 1994-04-21 | 2003-11-17 | シスメックス株式会社 | 白血球分析用試薬及び白血球の分類方法 |
| JP3324050B2 (ja) * | 1994-10-31 | 2002-09-17 | 日本光電工業株式会社 | 白血球分類用試薬および白血球分類方法 |
| US5691204A (en) * | 1995-04-21 | 1997-11-25 | Abbott Laboratories | Compositions and methods for the rapid analysis of reticulocytes |
| FR2735579B1 (fr) * | 1995-06-13 | 1997-09-19 | Hycel Groupe Lisabio | Procede de discrimination et d'isolement de sous-populations de leucocytes a partir d'echantillons sanguins par traitement par du polyoxyethylene 9-lauryl ether, et reactif pour sa mise en oeuvre |
| JP4042925B2 (ja) * | 1996-11-20 | 2008-02-06 | シスメックス株式会社 | 幼若白血球の分類計数法 |
| US5830701A (en) * | 1997-03-28 | 1998-11-03 | Tao Medical Electronics Co., Ltd. | Method of detecting hematopoietic progenitor cells |
| JP3783808B2 (ja) * | 1997-05-19 | 2006-06-07 | シスメックス株式会社 | 白血球分類計数用試薬 |
| KR19980042627A (ko) * | 1997-11-20 | 1998-08-17 | 이에츠구히사시 | 유약백혈구의 분류계수법 |
| US6225124B1 (en) * | 1999-06-02 | 2001-05-01 | Sysmex Corporation | Diluting reagent and method compelling time-independent consistency in MCV assay |
| US6900023B1 (en) | 1999-09-02 | 2005-05-31 | Sysmex Corporation | Method for classifying and counting leukocytes |
| US6916658B2 (en) * | 2001-07-27 | 2005-07-12 | Beckman Coulter, Inc. | Method for measurement of immature granulocytes |
| JP4227019B2 (ja) * | 2001-10-23 | 2009-02-18 | デンカ生研株式会社 | 血液中の血球と菌の分離方法および血液中の菌の検出方法 |
| JP4212827B2 (ja) * | 2002-05-16 | 2009-01-21 | シスメックス株式会社 | 骨髄液有核細胞自動分析方法 |
| DE60326603D1 (de) | 2002-06-24 | 2009-04-23 | Sysmex Corp | Verfahren zur klassifizierung und zählung von leukozyten |
| JP4118618B2 (ja) * | 2002-07-01 | 2008-07-16 | シスメックス株式会社 | 試料分析装置 |
| US20040166540A1 (en) * | 2003-02-24 | 2004-08-26 | Sysmex Corporation | Methods of detecting CD34 positive and negative hematopoietic stem cells in human samples |
| US7678578B2 (en) | 2005-02-07 | 2010-03-16 | Beckman Coulter, Inc. | Cell permeabilization and stabilization reagent and method of use |
| US7541190B2 (en) * | 2005-02-07 | 2009-06-02 | Beckman Coulter, Inc. | Method of measurement of cellular hemoglobin |
| JP4806342B2 (ja) * | 2006-01-27 | 2011-11-02 | シスメックス株式会社 | 幼若白血球分析用試薬及び試薬キット |
| US7625757B2 (en) * | 2006-01-27 | 2009-12-01 | Sysmex Corporation | Reagent for immature leukocyte analysis and reagent kit |
| JP4976038B2 (ja) * | 2006-03-29 | 2012-07-18 | シスメックス株式会社 | 血液学的試料の測定方法 |
| JP4806334B2 (ja) * | 2006-11-27 | 2011-11-02 | シスメックス株式会社 | 血液学的試料の測定方法および測定装置 |
| ES2684695T3 (es) * | 2007-06-25 | 2018-10-04 | Sysmex Corporation | Reactivo y kit de reactivos para el análisis de leucocitos primitivos |
| JP5214603B2 (ja) * | 2007-06-25 | 2013-06-19 | シスメックス株式会社 | 幼若白血球の分析用試薬及び分析用試薬キット |
| CN101349644B (zh) * | 2007-07-20 | 2012-06-27 | 深圳迈瑞生物医疗电子股份有限公司 | 一种白细胞分类试剂和其使用方法 |
| CN105440725A (zh) * | 2008-01-04 | 2016-03-30 | 深圳迈瑞生物医疗电子股份有限公司 | 不对称菁类荧光染料，组合物及在生物样品染色中的用途 |
| WO2009133928A1 (ja) * | 2008-05-02 | 2009-11-05 | アークレイ株式会社 | 白血球の分析方法およびそれに使用する分析試薬 |
| CN101602762B (zh) * | 2008-06-10 | 2013-10-16 | 深圳迈瑞生物医疗电子股份有限公司 | 不对称菁类化合物、其制备方法及应用 |
| CN101726579B (zh) * | 2008-10-17 | 2014-06-18 | 深圳迈瑞生物医疗电子股份有限公司 | 血液检测试剂和方法 |
| CN101723874B (zh) * | 2008-10-31 | 2013-09-11 | 深圳迈瑞生物医疗电子股份有限公司 | 花菁类化合物及其在生物样品染色中的用途 |
| JP5168658B2 (ja) * | 2008-11-21 | 2013-03-21 | 国立大学法人高知大学 | 血球分析装置、血球分析方法及びコンピュータプログラム |
| CN101750476B (zh) * | 2008-12-08 | 2015-06-03 | 深圳迈瑞生物医疗电子股份有限公司 | 血液分析试剂及其使用方法 |
| US8367358B2 (en) * | 2008-12-17 | 2013-02-05 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Reagent, kit and method for differentiating and counting leukocytes |
| CN101988082B (zh) * | 2009-07-31 | 2015-04-08 | 深圳迈瑞生物医疗电子股份有限公司 | 白细胞分类计数试剂、试剂盒及其制备方法和白细胞分类计数的方法 |
| JP5416232B2 (ja) * | 2012-01-23 | 2014-02-12 | シスメックス株式会社 | 血液学的試料の測定装置 |
| MX368543B (es) * | 2012-02-08 | 2019-10-07 | Univ Florida | Composiciones para tratar diarrea inducida por rotavirus. |
| JP6319959B2 (ja) * | 2013-07-05 | 2018-05-09 | 国立大学法人信州大学 | 白血球数及び左方移動を指標とした細菌感染症の検出 |
| WO2016106688A1 (zh) * | 2014-12-31 | 2016-07-07 | 深圳迈瑞生物医疗电子股份有限公司 | 一种有核红细胞报警方法、装置及流式细胞分析仪 |
| KR101849698B1 (ko) * | 2017-08-24 | 2018-04-18 | 한국화학연구원 | 생체 조직 크기 조절용 조성물 및 상기 조성물을 이용한 생체 조직의 크기 조절 방법 |
| KR20190094509A (ko) * | 2018-02-05 | 2019-08-14 | 한국화학연구원 | 스페로이드 투명화용 조성물, 이를 이용한 스페로이드 투명화 방법 및 이를 포함하는 키트 |
| CN111024563A (zh) * | 2019-12-30 | 2020-04-17 | 深圳开立生物医疗科技股份有限公司 | 一种白细胞分类试剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099917A (en) | 1977-07-21 | 1978-07-11 | Technicon Instruments Corporation | Process for preparing a cell suspension from blood for discrimination of white blood cells and platelets from other blood particles |
| EP0044240A1 (de) | 1980-06-27 | 1982-01-20 | Union Carbide Corporation | Nichtwässrige Zellen enthaltend Kathoden aus wärmebehandeltem Mangandioxid und einen Elektrolyten von Propylencarbonat-dimethoxyäthan-lithium-trifluormethylsulfonat |
| US4751179A (en) | 1984-05-31 | 1988-06-14 | Coulter Electronics, Inc. | Method and reagents for differential determination of four populations of leukocytes in blood |
| WO1988009504A1 (en) | 1987-05-29 | 1988-12-01 | Toa Medical Electronics Co., Ltd. | Method for classifying leukocytes and reagents |
| JP2935529B2 (ja) * | 1990-03-01 | 1999-08-16 | シスメックス株式会社 | 白血球分類方法および試薬 |
| JP2778745B2 (ja) * | 1989-06-19 | 1998-07-23 | 東亜医用電子株式会社 | 血液中の白血球弁別測定用試薬 |
| JP2836865B2 (ja) * | 1989-10-23 | 1998-12-14 | 東亜医用電子株式会社 | 血液中の白血球およびヘモグロビンの測定用試薬 |
| US5242832A (en) * | 1990-03-01 | 1993-09-07 | Toa Medical Electronics Co., Ltd. | Reagent for measurement of leukocytes and hemoglobin in blood |
| DE4018502A1 (de) * | 1990-06-09 | 1991-12-12 | Merck Patent Gmbh | Verfahren und mittel zur beseitigung von truebungen in biologischen fluessigkeiten |
| CA2048302A1 (en) * | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
| DE69327775T2 (de) * | 1992-11-19 | 2000-06-21 | Sysmex Corp., Kobe | Verfahren zur Vorbehandlung für Blutanalyse |
-
1993
- 1993-03-19 JP JP06003793A patent/JP3301646B2/ja not_active Expired - Lifetime
- 1993-12-28 TW TW082111061A patent/TW297093B/zh not_active IP Right Cessation
-
1994
- 1994-03-17 DE DE69419053T patent/DE69419053T2/de not_active Expired - Lifetime
- 1994-03-17 AU AU57856/94A patent/AU665508B2/en not_active Expired
- 1994-03-17 US US08/214,248 patent/US5413938A/en not_active Expired - Lifetime
- 1994-03-17 ES ES94400580T patent/ES2132352T3/es not_active Expired - Lifetime
- 1994-03-17 EP EP94400580A patent/EP0617281B1/de not_active Expired - Lifetime
- 1994-03-18 CA CA002119390A patent/CA2119390C/en not_active Expired - Lifetime
- 1994-03-19 CN CN94102901A patent/CN1088194C/zh not_active Expired - Lifetime
- 1994-03-19 KR KR1019940005602A patent/KR100287583B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2132352T3 (es) | 1999-08-16 |
| KR940022088A (ko) | 1994-10-20 |
| EP0617281B1 (de) | 1999-06-16 |
| US5413938A (en) | 1995-05-09 |
| JP3301646B2 (ja) | 2002-07-15 |
| CN1095481A (zh) | 1994-11-23 |
| DE69419053D1 (de) | 1999-07-22 |
| AU5785694A (en) | 1994-09-22 |
| DE69419053T2 (de) | 1999-10-21 |
| EP0617281A2 (de) | 1994-09-28 |
| KR100287583B1 (ko) | 2001-05-02 |
| JPH06273413A (ja) | 1994-09-30 |
| CA2119390C (en) | 1997-04-08 |
| AU665508B2 (en) | 1996-01-04 |
| EP0617281A3 (de) | 1995-09-06 |
| CA2119390A1 (en) | 1994-09-20 |
| CN1088194C (zh) | 2002-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW297093B (de) | ||
| Nussenblatt et al. | Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria | |
| Orfanakis et al. | Normal blood leukocyte concentration values | |
| JP2619900B2 (ja) | 血液中の白血球およびヘモグロビンの測定用試薬および方法 | |
| JP2935529B2 (ja) | 白血球分類方法および試薬 | |
| Thomson et al. | Iron deficiency in inflammatory bowel disease: diagnostic efficacy of serum ferritin | |
| Kursun et al. | Effects of X-rays and magnetic resonance imaging on mercury release from dental amalgam into artificial saliva | |
| Elsayh et al. | Leukocytes apoptosis and adipocytokines in children with beta thalassemia major | |
| Benga et al. | On measuring the diffusional water permeability of human red blood cells and ghosts by nuclear magnetic resonance | |
| Omarine Nlinwe et al. | Assessment of hematological parameters in malaria, among adult patients attending the Bamenda Regional Hospital | |
| Sharma et al. | Protective Role of β-arrestin2 in Colitis Through Modulation of T-cell Activation | |
| Karim et al. | Anaemia in pregnancy-its cause in the underprivileged class of Karachi | |
| Peterson et al. | Dose range-finding toxicity study in rats with recombinant human lactoferrin produced in Komagataella phaffii | |
| AL-Zuhairy et al. | Evaluation of Reproductive Hormones in Patients with β-Thalassemia Major in Misan Province, Iraq. | |
| Nakama et al. | Colorectal cancer in iron deficiency anemia with a positive result on immunochemical fecal occult blood | |
| Dorneles et al. | Levels of cardiorespiratory fitness in men exerts strong impact on lymphocyte function after mitogen stimulation | |
| Teległów et al. | EFFECTS OF WINTER SWIMMING AND WHOLE-BODY CRYOTHERAPY ON THE HEMATOLOGICAL AND RHEOLOGICAL PROPERTIES OF BLOOD IN REGULAR WINTER SWIMMERS AND INDIVIDUALS EXPOSED TO WHOLE-BODY CRYOTHERAPY. | |
| Nikhar et al. | An anthropometric and hematological comparison of sickle cell disease children from rural and urban areas | |
| Yalçin et al. | The validity of pallor as a clinical sign of anemia in cases with beta-thalassemia | |
| JP2635142B2 (ja) | 白血球分類方法および試薬 | |
| Zhang et al. | Measurement of the phagocytic activity of human peripheral blood using a highly sensitive fluorometric detection device without hemolysis | |
| JPH08500437A (ja) | 哺乳動物の血液の検体の抗原に対するアレルギー誘発応答を決定する方法 | |
| Kędziora et al. | Down syndrome—transferrin parallels plasma iron changes | |
| Droste et al. | Single extracellular vesicle analysis performed by imaging flow cytometry in contrast to NTA rigorously assesses the accuracy of urinary extracellular vesicle preparation techniques | |
| ElSawy | Nutritional Status, Anthropometric and Biochemical Profile of Down Syndrome Children with Cancer at King Abdullah Medical City Hospital in Makkah |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |